Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.
BBC and Boxxer partner to bring live, world-class professional boxing back to national television and digital platforms.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.
BBC and Boxxer partner to bring live, world-class professional boxing back to national television and digital platforms.